SAN DIEGO, Nov. 14, 2012 (GLOBE NEWSWIRE) -- MediciNova, Inc. a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange (Code Number: 4875), announced that Dr. Kazuko Matsuda, Chief Medical Officer, will present the results of the phase 2 clinical trial of MN-221 in acute exacerbation of asthma at the Fourth World Congress of Emergency Medicine being held in Cancun, Mexico November 14 through 17.
